194 related articles for article (PubMed ID: 31319410)
1. Effect of the Tryptophan Hydroxylase Inhibitor Telotristat on Growth and Serotonin Secretion in 2D and 3D Cultured Pancreatic Neuroendocrine Tumor Cells.
Herrera-Martínez AD; Feelders RA; Van den Dungen R; Dogan-Oruc F; van Koetsveld PM; Castaño JP; de Herder WW; Hofland LJ
Neuroendocrinology; 2020; 110(5):351-363. PubMed ID: 31319410
[TBL] [Abstract][Full Text] [Related]
2. Telotristat ethyl: a new option for the management of carcinoid syndrome.
Lamarca A; Barriuso J; McNamara MG; Hubner RA; Valle JW
Expert Opin Pharmacother; 2016 Dec; 17(18):2487-2498. PubMed ID: 27817224
[TBL] [Abstract][Full Text] [Related]
3. Does Telotristat Have a Role in Preventing Carcinoid Heart Disease?
Herrera-Martínez AD; Fuentes-Fayos AC; Sanchez-Sanchez R; Montero AJ; Sarmento-Cabral A; Gálvez-Moreno MA; Gahete MD; Luque RM
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396713
[TBL] [Abstract][Full Text] [Related]
4. Telotristat Ethyl: First Global Approval.
Markham A
Drugs; 2017 May; 77(7):793-798. PubMed ID: 28382568
[TBL] [Abstract][Full Text] [Related]
5. Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors.
Herrera-Martínez AD; van den Dungen R; Dogan-Oruc F; van Koetsveld PM; Culler MD; de Herder WW; Luque RM; Feelders RA; Hofland LJ
Endocr Relat Cancer; 2019 Jun; 26(6):585-599. PubMed ID: 30939452
[TBL] [Abstract][Full Text] [Related]
6. Telotristat ethyl: a novel agent for the therapy of carcinoid syndrome diarrhea.
Dillon JS; Chandrasekharan C
Future Oncol; 2018 May; 14(12):1155-1164. PubMed ID: 29350062
[TBL] [Abstract][Full Text] [Related]
7. Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea.
Masab M; Saif MW
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1055-1062. PubMed ID: 29051994
[TBL] [Abstract][Full Text] [Related]
8. Telotristat ethyl for the treatment of carcinoid syndrome diarrhea not controlled by somatostatin analogues.
Kasi PM
Drugs Today (Barc); 2018 Jul; 54(7):423-432. PubMed ID: 30090879
[TBL] [Abstract][Full Text] [Related]
9. Telotristat Ethyl: A Review in Carcinoid Syndrome Diarrhoea.
Lyseng-Williamson KA
Drugs; 2018 Jun; 78(9):941-950. PubMed ID: 29931594
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors.
Molina-Cerrillo J; Alonso-Gordoa T; Martínez-Sáez O; Grande E
Oncologist; 2016 Jun; 21(6):701-7. PubMed ID: 27107003
[TBL] [Abstract][Full Text] [Related]
11. TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World.
Strosberg J; Joish VN; Giacalone S; Perez-Olle R; Fish-Steagall A; Kapoor K; Dharba S; Lapuerta P; Benson AB
Oncologist; 2019 Nov; 24(11):1446-1452. PubMed ID: 31189618
[TBL] [Abstract][Full Text] [Related]
12. The journey from gene knockout to clinical medicine: telotristat and sotagliflozin.
Rendell MS
Drug Des Devel Ther; 2019; 13():817-824. PubMed ID: 30880915
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome.
Anthony LB; Kulke MH; Caplin ME; Bergsland E; Öberg K; Pavel M; Hörsch D; Warner RRP; O'Dorisio TM; Dillon JS; Lapuerta P; Kassler-Taub K; Jiang W
Oncologist; 2019 Aug; 24(8):e662-e670. PubMed ID: 30651397
[TBL] [Abstract][Full Text] [Related]
14. Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome.
Weickert MO; Kaltsas G; Hörsch D; Lapuerta P; Pavel M; Valle JW; Caplin ME; Bergsland E; Kunz PL; Anthony LB; Grande E; Öberg K; Welin S; Lombard-Bohas C; Ramage JK; Kittur A; Yang QM; Kulke MH
Clin Ther; 2018 Jun; 40(6):952-962.e2. PubMed ID: 29724499
[TBL] [Abstract][Full Text] [Related]
15. Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.
Kulke MH; Hörsch D; Caplin ME; Anthony LB; Bergsland E; Öberg K; Welin S; Warner RR; Lombard-Bohas C; Kunz PL; Grande E; Valle JW; Fleming D; Lapuerta P; Banks P; Jackson S; Zambrowicz B; Sands AT; Pavel M
J Clin Oncol; 2017 Jan; 35(1):14-23. PubMed ID: 27918724
[TBL] [Abstract][Full Text] [Related]
16. Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures.
Mohamed A; Blanchard MP; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Monges G; Garcia S; Ferone D; Florio T; Enjalbert A; Moutardier V; Schonbrunn A; Gerard C; Barlier A; Saveanu A
Endocr Relat Cancer; 2014 Oct; 21(5):691-704. PubMed ID: 25012983
[TBL] [Abstract][Full Text] [Related]
17. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide.
Kulke MH; O'Dorisio T; Phan A; Bergsland E; Law L; Banks P; Freiman J; Frazier K; Jackson J; Yao JC; Kvols L; Lapuerta P; Zambrowicz B; Fleming D; Sands A
Endocr Relat Cancer; 2014 Oct; 21(5):705-14. PubMed ID: 25012985
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of serotonin synthesis: A novel therapeutic paradigm.
Bader M
Pharmacol Ther; 2020 Jan; 205():107423. PubMed ID: 31629717
[TBL] [Abstract][Full Text] [Related]
19. Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial.
Pavel M; Gross DJ; Benavent M; Perros P; Srirajaskanthan R; Warner RRP; Kulke MH; Anthony LB; Kunz PL; Hörsch D; Weickert MO; Lapuerta P; Jiang W; Kassler-Taub K; Wason S; Fleming R; Fleming D; Garcia-Carbonero R
Endocr Relat Cancer; 2018 Mar; 25(3):309-322. PubMed ID: 29330194
[TBL] [Abstract][Full Text] [Related]
20. Effects of Ketoconazole on ACTH-Producing and Non-ACTH-Producing Neuroendocrine Tumor Cells.
Herrera-Martínez AD; Feelders RA; de Herder WW; Castaño JP; Gálvez Moreno MÁ; Dogan F; van Dungen R; van Koetsveld P; Hofland LJ
Horm Cancer; 2019 Jun; 10(2-3):107-119. PubMed ID: 31102172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
